Literature DB >> 2765410

A non-human primate model for the study of oral iron chelators.

L C Wolfe1, R J Nicolosi, M M Renaud, J Finger, M Hegsted, H Peter, D G Nathan.   

Abstract

Recent studies have demonstrated that parenteral deferroxamine can prolong life in patients with iron overload. We have developed a non-human primate model of iron overload and have accurately determined negative iron balance in parenteral and oral studies of deferroxamine and a new chelator, desferrithiocin. Cebus monkeys were loaded with iron dextran (10 mg/kg twice weekly) until their serum contained a transferrin saturation greater than 75%, and (in two animals) liver biopsies showed iron loading. When complete iron balance studies were performed at this time, basal iron balance was -53 +/- 11 micrograms (N = 4), providing a low background for provocative studies. Iron balance was determined for intramuscular (N = 2) and oral (N = 3) deferroxamine, as well as intramuscular (N = 1) and oral (N = 4) desferrithiocin. The pattern of iron excretion after parenteral deferroxamine strongly resembled that of the iron-loaded, transfused human. Desferrithiocin was found to have significant activity as an oral chelator. This Cebus monkey model accurately determines negative iron balance and readily permits precise comparison of iron chelators given parenterally or orally. This model may offer an important step between rodent and human trials of promising new iron chelators.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2765410     DOI: 10.1111/j.1365-2141.1989.tb07732.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.

Authors:  Anthony Kicic; Anita C G Chua; Erica Baker
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles.

Authors:  Raymond J Bergeron; Jan Wiegand; Neelam Bharti; James S McManis
Journal:  J Med Chem       Date:  2012-08-13       Impact factor: 7.446

3.  Desferrithiocin analogue uranium decorporation agents.

Authors:  Raymond J Bergeron; Jan Wiegand; Shailendra Singh
Journal:  Int J Radiat Biol       Date:  2009-04       Impact factor: 2.694

4.  Metabolically programmed iron chelators.

Authors:  Raymond J Bergeron; Neelam Bharti; James S McManis; Jan Wiegand
Journal:  Bioorg Med Chem       Date:  2015-06-29       Impact factor: 3.641

Review 5.  The Efficacy of Iron Chelators for Removing Iron from Specific Brain Regions and the Pituitary-Ironing out the Brain.

Authors:  Robert R Crichton; Roberta J Ward; Robert C Hider
Journal:  Pharmaceuticals (Basel)       Date:  2019-09-17

Review 6.  Desferrithiocin: a search for clinically effective iron chelators.

Authors:  Raymond J Bergeron; Jan Wiegand; James S McManis; Neelam Bharti
Journal:  J Med Chem       Date:  2014-09-10       Impact factor: 7.446

Review 7.  Is Chelation Therapy a Potential Treatment for Parkinson's Disease?

Authors:  Roberta J Ward; David T Dexter; Antonio Martin-Bastida; Robert R Crichton
Journal:  Int J Mol Sci       Date:  2021-03-24       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.